<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511665</url>
  </required_header>
  <id_info>
    <org_study_id>METAL</org_study_id>
    <nct_id>NCT02511665</nct_id>
  </id_info>
  <brief_title>Metformin And Longevity</brief_title>
  <acronym>METAL</acronym>
  <official_title>METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blind, window of opportunity study&#xD;
      investigating the biological mechanism of metformin in prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A potential role for metformin in prostate cancer has been suggested and given its wide&#xD;
      availability, tolerable side effect profile and safety record it may represent a therapeutic&#xD;
      option for men with prostate cancer. However, the mechanism of action by which metformin&#xD;
      exerts its anti-cancer effect has yet to be fully characterised. This 'window of opportunity'&#xD;
      trial provides an opportunity to investigate this by comparing baseline prostate biopsies&#xD;
      with post-treatment surgical specimen by focussing on assessment of the FASN/AMPK axis.&#xD;
&#xD;
      Patients with newly-diagnosed, early stage, prostate cancer scheduled for radical&#xD;
      prostatectomy will either enter the main study and be randomised 1:1 to receive metformin (2g&#xD;
      daily over 2 divided doses; Arm A) or placebo four weeks prior to prostatectomy (standard of&#xD;
      care; Arm B). Or a subset of five patients will enter the exploratory PET-MRI Substudy .&#xD;
      These five patients will all receive metformin and will undergo an additional two PET-MRI&#xD;
      Scans.&#xD;
&#xD;
      Prostate tissue (at baseline from biopsy and post treatment from prostatectomy) will be used&#xD;
      for analysis of p-AMPK, p-ACC, FASN by immunohistochemistry and proliferation will be&#xD;
      measured using Ki67 and TUNEL in both metformin and placebo groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the difference in expression levels of markers of the FASN/AMPK pathway pre and post treatment between the placebo and metformin arms.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin given , 1g twice a day for 4 weeks until prostatectomy +/- one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo given , 1g twice a day for 4 weeks until prostatectomy +/- one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PET-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 patients in this arm will all receive metformin and undergo two additional PET- MRI scans, one before and one after treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Given metformin</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET-MRI Scan</intervention_name>
    <description>Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after</description>
    <arm_group_label>PET-MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or older and willing and able to provide signed informed consent.&#xD;
&#xD;
          2. Histologically confirmed adenocarcinoma of the prostate , with a minimum maximal&#xD;
             tumour length of greater than 6mm on core biopsy&#xD;
&#xD;
          3. No previous treatment for prostate cancer (including surgery, any hormone therapy,&#xD;
             radiotherapy and cryotherapy)&#xD;
&#xD;
          4. Prostate biopsy within 8 weeks from screening which contains sufficient material for&#xD;
             baseline molecular marker assessment at Guy's and St Thomas' NHS Foundation trust..&#xD;
&#xD;
          5. Radical prostatectomy is the scheduled treatment of choice&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 0&#xD;
             or 1.&#xD;
&#xD;
          7. Adequate organ function, defined as follows:&#xD;
&#xD;
               -  Haemoglobin &gt;10.0g/dL&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1.5x109/L&#xD;
&#xD;
               -  Platelet count &gt;100x109/L&#xD;
&#xD;
               -  Renal function, eGFR &gt;60ml/min (calculated by Cockcroft Gault)&#xD;
&#xD;
               -  AST and/or ALT &lt;2.5 x ULN&#xD;
&#xD;
               -  Total Bilirubin &lt;1.5 x ULN&#xD;
&#xD;
          8. Able to swallow the drug and comply with study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a current or historical diagnosis of type one or two Diabetes and/or&#xD;
             have ever received metformin&#xD;
&#xD;
          2. Patients with hypersensitivity to any of the components of Metformin or placebo tablet&#xD;
&#xD;
          3. History of or conditions associated with lactic acidosis such as shock or pulmonary&#xD;
             insufficiency, alcoholism (acute or chronic), and conditions associated with&#xD;
             hypoxaemia&#xD;
&#xD;
          4. Patients with chronic liver disease, severe cardiovascular impairment, cardiac&#xD;
             failure, recent myocardial infarction, severe peripheral vascular disease or renal&#xD;
             impairment (eGFR &lt;60ml/min as measured by Cockcroft Gault)&#xD;
&#xD;
          5. Patients with acute severe disorders, for example infections with fever, pancreatitis,&#xD;
             trauma, dehydration or reduced diet (&lt;1000kcal or 4200kJ per day)&#xD;
&#xD;
          6. Other active malignancy over the last five years that has required systemic therapy,&#xD;
             excluding:&#xD;
&#xD;
               -  Adjuvant therapy in the curative setting&#xD;
&#xD;
               -  Non-melanoma skin cancer&#xD;
&#xD;
               -  Superficial transitional cell carcinoma (CIS-T1)&#xD;
&#xD;
          7. Current enrolment in an investigational drug or device study or participation in such&#xD;
             a study within 30 days of signing consent.&#xD;
&#xD;
          8. Any subjects who is able to father a child and does not agree to use barrier&#xD;
             protection, in the form of a condom ,for the duration of the trial and for 16 weeks&#xD;
             after the last study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Rudman, MBBS BSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Danielle Crawley, MBBS</last_name>
      <phone>02071887904</phone>
      <email>danielle.crawley@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

